These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 20829538)

  • 1. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
    Niekel MC; Bipat S; Stoker J
    Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.
    Bipat S; van Leeuwen MS; Comans EF; Pijl ME; Bossuyt PM; Zwinderman AH; Stoker J
    Radiology; 2005 Oct; 237(1):123-31. PubMed ID: 16100087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis.
    Tsili AC; Alexiou G; Naka C; Argyropoulou MI
    Acta Radiol; 2021 Mar; 62(3):302-312. PubMed ID: 32506935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
    Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
    Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
    Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
    Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET.
    Chen YK; Chen JH; Tsui CC; Chou HH; Cheng RH; Chiu JS
    Radiology; 2011 May; 259(2):525-33. PubMed ID: 21406631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.
    van Kessel CS; Buckens CF; van den Bosch MA; van Leeuwen MS; van Hillegersberg R; Verkooijen HM
    Ann Surg Oncol; 2012 Sep; 19(9):2805-13. PubMed ID: 22396005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
    Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
    Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
    Kinkel K; Lu Y; Both M; Warren RS; Thoeni RF
    Radiology; 2002 Sep; 224(3):748-56. PubMed ID: 12202709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
    Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI.
    Schulz A; Viktil E; Godt JC; Johansen CK; Dormagen JB; Holtedahl JE; Labori KJ; Bach-Gansmo T; Kløw NE
    Acta Radiol; 2016 Sep; 57(9):1040-8. PubMed ID: 26622057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
    Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
    Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of liver metastases in patients with adenocarcinomas of the gastrointestinal tract: comparison of (18)F-FDG PET/CT and MR imaging.
    Maegerlein C; Fingerle AA; Souvatzoglou M; Rummeny EJ; Holzapfel K
    Abdom Imaging; 2015 Jun; 40(5):1213-22. PubMed ID: 25348732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
    Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.
    Mainenti PP; Mancini M; Mainolfi C; Camera L; Maurea S; Manchia A; Tanga M; Persico F; Addeo P; D'Antonio D; Speranza A; Bucci L; Persico G; Pace L; Salvatore M
    Abdom Imaging; 2010 Oct; 35(5):511-21. PubMed ID: 19562412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging.
    Lee DH; Lee JM; Hur BY; Joo I; Yi NJ; Suh KS; Kang KW; Han JK
    Radiology; 2016 Sep; 280(3):782-92. PubMed ID: 27092659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis.
    Liu T; Xu JY; Xu W; Bai YR; Yan WL; Yang HL
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):350-8. PubMed ID: 21094027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.